Astria Therapeutics (ATXS) has released an update.
The Company announced the pricing of its Offering on January 30, 2024, and expects that the resulting net proceeds, combined with its current financial assets, will fund its operations and capital expenditures into mid-2027. This includes the development of its product candidates STAR-0215 and STAR-0310, through various stages of clinical trials and regulatory milestones. However, the funds raised are not anticipated to cover the complete development of these or any future product candidates, and the Company acknowledges that its financial estimates could be inaccurate, potentially leading to an earlier depletion of its capital resources.
For further insights into ATXS stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
